Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).
Back to dashboard
Company Information
About this company
Key people
Amit D. Munshi
Independent Chairman of the Board
Christopher H. Cabell
President, Head - Research and Development
Mark T. Iwicki
Chief Executive Officer, Director
David Mcintyre
Chief Financial Officer
Vincent E. Aurentz
Independent Director
Roberto Bellini
Independent Director
Dennis N. Berman
Independent Director
David Canner
Independent Director
Click to see more
Key facts
- Shares in issue139.54m
- EPICIKT
- ISINUS45719W2052
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$245.58m
- Employees35
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.